PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
99.24
Current Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 2.37. Joel Greenblatt would see extra liquidity as a cushion for downturns.
99.24
Quick Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 1.60. Joel Greenblatt would see a superior short-term safety net.
0.48
Cash Ratio 0.75–0.9x Drug Manufacturers - Specialty & Generic median of 0.60. John Neff could push for improved balance sheet strength.
-5.29
Negative interest coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize earnings quality and look for debt restructuring catalysts.
No Data
No Data available this quarter, please select a different quarter.